Ix Biopharma Ltd. · SGX:42C
Ix Biopharma — Shareholder Meeting (October 2022)
23 slides from Ix Biopharma's shareholder meeting presentation, October 2022
Slide 1: Management Update FY2022
iX Biopharma Ltd Management Update FY2022
Slide 2: Disclaimer
DISCLAIMER The information in this presentation has not been independently verified. iX Biopharma Ltd (the “Company”) makes no representation or warranty (whether express or implied) whatsoever in this presentation, & no reliance should be placed on the information or opinions contained in this pres
Slide 3: COVID-19 and Economic Uncertainty
COVID-19 and Economic Uncertainty ➢ Past 2 years of COVID-19 pandemic negatively impacted the global economy • Border closures, travel restrictions, home quarantine etc • Affecting consumption and spending, and supply chain disruptions • Investment confidence shaken ➢ Covid-19 restrictions easing, h
Slide 4: Solid FY2022 Performance
Solid FY2022 Performance FY2022 FY2021 Variance S$’000 S$’000 S$’000 % Product and services 2,018 1,745 273 16% Out-licensing 12,372 - 12,372 - Total revenue 14,390 1,745 12,645 725% Profit/(Loss) before tax excluding foreign exchange and 1,071 (10,028) 10,950 - fair value loss ➢ First profit before
Slide 5: Biotech Stock Indicators
Biotech Stock Indicators Hang Seng Hong Kong-Listed Biotech Index ↓ 42% from Nov21- Sep22 ↓ 42% from Nov21- Sep22 ↓ 53% from Nov21- Sep22 Confidential 5
Slide 6: FY2022 Highlights
FY2022 Highlights ➢ Wafermine out-licensed to Seelos Therapeutics ✓ Received US$9 million in cash and shares ✓ Eligible for US$239 million in development and sales milestone payments, plus double digit percentage royalties on sales ➢ Wafesil out-licensed to China Resources Pharmaceutical Commercial
Slide 7: Strengthened Financial Position
Strengthened Financial Position ➢ Rights issue raised S$9.62 million on 26 July 2021, oversubscribed by 196.2% ➢ Private placement raised $2.71 million on 21 July 2022 Confidential 7
Slide 8: Pharmaceuticals
Pharmaceuticals Confidential
Slide 9: Expansion of Pharmaceutical Pipeline
Expansion of Pharmaceutical Pipeline S/N Active Indication Stage Remarks Pre Pharmaceuticals P1 P2 P3 Approval Clinical Approved in AU; 1 Wafesil Male Erectile Dysfunction Out-licensed to China Resources Pharmaceutical Group in Sep 21 Acute Pain Out-licensed to Seelos Wafermine 2 Complex Regional Pa
Slide 10: Wafermine Update
Wafermine Update ➢ Wafermine will be developed by Seelos for the treatment of Complex Regional Pain Syndrome (CRPS) ➢ The Company was granted orphan drug designation for ketamine to treat CRPS. Seelos has designated this program as SLS-003. The intended development plan is as follows: i. Phase 2 stu
Slide 11: Sublingual Dexmedetomidine
Sublingual Dexmedetomidine ➢ Approved as IV infusion for procedural sedation, repurposed for dementia-related agitation ➢ Phase 1 (PK) study “DEX-001” conducted in Melbourne, Australia ✓ Results expected ~ Dec 2022/Jan 2023 ✓ US FDA IND to be filed 1Q 2023 ✓ Internally funded ➢ Unmet need: No FDA-ap
Slide 12: Sublingual Dronabinol
Sublingual Dronabinol ➢ Synthetic THC & is an approved pharmaceutical drug ➢ Approved indications: 1) treatment of chemotherapy-induced nausea and vomiting (CINV) 2) anorexia associated with weight loss due to HIV/AIDS ➢ Current products are oral capsule (Marinol) and oral liquid (Syndros) for inges
Slide 13: Sublingual Apomorphine
Sublingual Apomorphine ➢ Apomorphine is currently approved for the treatment of motor symptoms of Parkinson’s Disease (PD) ➢ PD patients experience “off-episodes”, periods when patients experience worsening motor symptoms despite being on medication due to; 1) short half-life 2) variable absorption
Slide 14: Medicinal Cannabis
Medicinal Cannabis Confidential
Slide 15: Market Update (AU/UK)
Market Update (AU/UK) 1) Australia a) Xativa CBD wafers supplied with prescription b) Hypera (THC) 5mg and 10mg wafers launched in October 2022 c) ~200 doctors now prescribing Xativa and Hypera 2) United Kingdom a) CBD Novel Food ✓ Filed UK FSA application in Mar 2021 to market Xativa as food (OTC)
Slide 16: US Market Opportunity
US Market Opportunity ➢ US market size for legal cannabis is ~$18.4B in 2022, increasing to ~US$25.1B by 2025 ➢ Potential market dominance with new technology & new wellness products ✓ CBD sales and use is becoming mainstream ✓ No dominant player, no new product innovation ✓ Opportunity to dominate
Slide 17: US Market Opportunity
US Market Opportunity ➢ Participating in MJ Bizcon Conference, the largest US cannabis conference in Las Vegas, 15-18 November 2022 ✓ 35,000 attendees, 1,300 exhibitors, 320,000 square feet of exhibits and 130 speakers Confidential 17
Slide 18: Nutraceuticals
Nutraceuticals Confidential
Slide 19: Market Update
Market Update ➢ 44% of total sales in FY22 in May and June due to; ✓ Carefully calibrated sales programs (e.g. increased livestreams and other marketing activities) ➢ China still locked down, consumer spending remains uncertain ➢ Supply chain remains hampered by COVID related regulations ✓ Increased
Slide 20: LumeniX Clinical Study Results
LumeniX Clinical Study Results Randomised, double blind, placebo controlled, multiple dose trial of the efficacy and safety of a sublingual glutathione wafer as a therapeutic skin health supplement. Results of study*: ➢ in 4 weeks: ✓ Increase skin luminosity by up to 66% ✓ Reduce melanin by up to 40
Slide 21: Proposed Spin Off Update
Proposed Spin Off Update Confidential
Slide 22: Proposed Spin off & Listing on HKEX
Proposed Spin off & Listing on HKEX ➢ As previously announced, we engaged listing professionals to advise Hang Seng Hong Kong-Listed Biotech Index us on the HKEX Chapter 18A listing ➢ Global economy remains uncertain due to ✓ geopolitical instability and conflicts ✓ surging inflation ✓ volatile ener
Slide 23: Thank You
Thank You = SS Ss